The Angiogenesis Inhibitor ALS-L1023 from Lemon-Balm Leaves Attenuates High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease through Regulating the Visceral Adipose-Tissue Function

Jeongjun Kim 1, Haerim Lee 1, Jonghoon Lim 1, Jaeho Oh 1, Soon Shik Shin 2 and Michung Yoon 1,*

1 Department of Biomedical Engineering, Mokwon University, Daejeon 35349, Korea; sdsd2586@naver.com (J.K.); lhr6515@naver.com (H.L.); tbvwhdlsdl@naver.com (J.L.); kelberoth30@naver.com (J.O.)
2 Department of Formula Sciences, College of Korean Medicine, Dongeui University, Busan 47340, Korea; ss shin@deu.ac.kr
* Correspondence: yoon60@mokwon.ac.kr; Tel.: +82-42-829-7581; Fax: +82-42-829-7580

Academic Editor: Marica Bakovic
Received: 3 March 2017; Accepted: 12 April 2017; Published: 17 April 2017

Abstract: Similar to neoplastic tissues, growth and development of adipose tissue are thought to be angiogenesis-dependent. Since visceral adipose tissue (VAT) is associated with development and progression of nonalcoholic fatty liver disease (NAFLD), we hypothesized that angiogenesis inhibition would attenuate obesity-induced NAFLD. We fed C57BL/6J mice a low-fat diet (LFD, chow 10% kcal fat), a high-fat diet (HFD, 45% kcal fat) or HFD supplemented with the lemon-balm extract ALS-L1023 (HFD-ALS) for 15 weeks. ALS-L1023 reduced endothelial cell-tube formation in vitro. HFD increased VAT angiogenesis and induced weight gains including body weight, VAT mass and visceral adipocyte size compared with LFD. However, HFD-ALS led to weight reductions without affecting calorie intake compared with HFD. HFD-ALS also reduced serum ALT and AST levels and improved lipid metabolism. HFD-ALS suppressed steatosis, infiltration of inflammatory cells, and accumulation of collagen in livers. HFD-ALS modulated hepatic expression of genes involved in lipid metabolism, inflammation, fibrosis, antioxidation, and apoptosis. Concomitantly, analysis of VAT function revealed that HFD-ALS led to fewer CD68-positive macrophage numbers and lower expression of inflammatory cytokines compared with HFD. Our findings show that the anti-angiogenic herbal extract ALS-L1023 attenuates NAFLD by targeting VAT during obesity, suggesting that angiogenesis inhibitors could aid in the treatment and prevention of obesity-induced human NAFLD.

Keywords: herbal medicine; Melissa officinalis; visceral adipose inflammation; visceral obesity

1. Introduction

Angiogenesis—the formation of new blood vessels from pre-existing vessels—is a strictly regulated process. Under normal physiological conditions, angiogenesis takes place only during embryonic development, wound healing, and menstruation [1]. Failure in the regulation of angiogenesis is correlated with many diseases such as cancer, rheumatoid arthritis, psoriasis, and proliferative retinopathy [2,3]. Similar to neoplastic tissues, angiogenesis occurs in the growing adipose tissue of adults [4]. Most tissues normally do not grow throughout adulthood and the supporting vasculature is
quiescent [5], whereas adipose tissue can grow and regress throughout life. The growth and expansion of adipose tissue requires the formation of new blood vessels to provide oxygen and nutrients to adipocytes [6]. It is suggested, therefore, that adipose tissue growth is angiogenesis-dependent and may be inhibited by angiogenesis inhibitors. Recently, we demonstrated that the anti-angiogenic dietary supplement Ob-X reduces adipose tissue mass and suppresses obesity by inhibiting angiogenesis [7].

Nonalcoholic fatty liver disease (NAFLD) directly affects 10–30% of the human population and is characterized by pathological alterations ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), fibrosis, and irreversible cirrhosis. NAFLD is considered a hepatic component of metabolic syndromes and is thus strongly associated with metabolic diseases such as obesity, insulin resistance, hypertension, and dyslipidemia [8]. The prevalence of NAFLD is strongly associated with obesity and the metabolic complications of over-nutrition, which usually accompany visceral obesity [9]. Visceral obesity is particularly associated with NAFLD [10,11]. The amount of visceral fat is directly linked to the severity of liver inflammation and fibrosis in NAFLD [10,12]. Human and animal studies indicate that NAFLD is strongly associated with VAT inflammation and elevated circulating inflammatory factors such as inflammatory adipokines and lipids [13–15]. It is reasonable that targeting visceral adipose tissue (VAT) can contribute to the treatment and prevention of NAFLD. Accordingly, we thought it plausible that the anti-angiogenic-induced VAT loss may attenuate NAFLD during obesity.

It is reported that development of obesity and NAFLD is associated with several risk factors including high calorie intake, low physical activity, and genetic predisposition. While total calorie intake is a critical factor in NAFLD, specific nutrients also play important roles in the development and progression of NAFLD. High-fat diet (HFD), Western (high fat and high sucrose) diet, high-fructose diet, high-fat and high-cholesterol diet, and a combination of fructose and moderate alcohol have been implicated as causes of fatty liver, steatohepatitis, and fibrosis [16–20].

We previously found that an active fraction, denominated ALS-L1023, of an organic extraction from lemon balm (Melissa officinalis L.) leaves exhibited anti-angiogenic activities [21,22]. Here, we examined the effects of ALS-L1023 on angiogenesis, visceral obesity, and obesity-induced NAFLD in HFD-fed C57BL/6J mice and investigated its mechanism of action. We found that the anti-angiogenic herbal extract ALS-L1023 ameliorates visceral obesity and obesity-induced NAFLD by inhibiting VAT angiogenesis and reducing VAT mass. Our data support previous reports that high VAT mass is an independent risk factor for NAFLD. Our results suggest that angiogenesis inhibition can regulate obesity-induced NAFLD by regulating VAT function.

2. Results

2.1. Effects of ALS-L1023 on Endothelial Cell-Tube Formation In Vitro

We tested ALS-L1023 for effects on angiogenesis in vitro using a human umbilical vein endothelial cell (HUVEC) tube-formation assay. Control HUVECs formed capillary-like tubular networks (Figure 1A). The addition of ALS-L1023 to these cultures inhibited the formation of capillary-like network in a dose-dependent manner (Figure 1B). However, vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) reversed the inhibition of endothelial cell-tube formation by ALS-L1023. These inhibitory effects on endothelial-cell proliferation were comparable to those of the well-known angiogenesis inhibitor TNP-470. Inhibition by ALS-L1023 was not due to cytotoxic effects because 2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxanilide disodium salt (XTT) assays showed that ALS-L1023 at concentrations between 0.1 and 10 µg/mL had no effects on HUVEC viability (Figure 1C).
Figure 1. Inhibitory effects of ALS-L1023 on endothelial cell-tube formation in vitro. (A) Tube formation of human endothelial cells. Cells were plated in Matrigel-coated wells and incubated with medium containing ALS-L1023, TNP-470, ALS-L1023 plus vascular endothelial growth factor (VEGF) or ALS-L1023 plus fibroblast growth factor (FGF). After incubation, capillary-like tube formation was photographed (original magnification ×100); (B) Inhibition of tube formation; (C) Human endothelial cell viability by 2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxanilide disodium salt (XTT) assay. All values are expressed as the mean ± SD (n = 9/group). *p < 0.05 compared with control. **p < 0.05 compared with ALS-L1023.

2.2. Effects of ALS-L1023 on VAT Vascularization in HFD-Fed Mice

To determine the ability of ALS-L1023 to inhibit VAT angiogenesis in vivo, we examined expression of von Willebrand Factor (vWF), a marker of endothelial cells, and real-time imaging of microcirculation within epididymal adipose tissue of mice fed a low fat diet (LFD), an HFD, and
HFD supplemented with ALS-L0123 (HFD-ALS). Staining of epididymal fat with an antibody against vWF showed that HFD-fed obese mice had much higher vWF-positive cells and blood-vessel density in LFD mice (Figure 2A,B), while ALS-L0123 obviously decreased HFD-induced increases in vWF-positive cells and blood-vessel density. In vivo measurements of VAT vasculature were also performed using a fibered confocal fluorescence microscopy (FCFM) imaging system. Fluorescence-signal density was lower in HFD-ALS mice than in HFD mice (Figure 2C,D). The expression profiles of genes involved in angiogenesis were investigated in epididymal adipose tissue. The mRNA expression of the angiogenic factor VEGF-A was significantly decreased, whereas the mRNA level of the anti-angiogenic factor thrombospondin-1 (TSP-1) was increased in HFD-ALS mice compared with HFD mice (Figure 2E).

**Figure 2.** Inhibitory effects of ALS-L1023 on VAT vasculature in vivo. Adult male C57BL/6J mice were fed a low-fat diet (LFD), a high-fat diet (HFD) or HFD supplemented with ALS-L1023 (HFD-ALS) for 15 weeks. (A) immunohistochemical detection of vWF-positive cells in the visceral adipose tissue (VAT) (original magnification ×100); (B) inhibition of blood vessel density by ALS-L1023; (C) real-time fibered confocal fluorescence microscopic images of VAT angiogenesis; (D) analysis of fluorescence density in the VAT; (E) the mRNA expression of vascular endothelial growth factor A (VEGF-A), fibroblast growth factor 2 (FGF-2), and thrombospondin-1 (TSP-1) in the VAT. All values are expressed as the mean ± SD (n = 5/group). # p < 0.05 compared with LFD. * p < 0.05 compared with HFD.
2.3. Effects of ALS-L1023 on Body Weight, Visceral Adipose-Tissue Mass, and Adipocyte Size in HFD Mice

To determine whether ALS-L1023 regulates visceral obesity, we measured body weight and visceral fat mass. After 15 weeks, HFD mice had higher body weights and VAT mass compared with LFD mice (Figure 3A,B). However, ALS-L1023 treatment significantly decreased HFD-induced increases in body weights and visceral fat mass. Similarly, ALS-L1023 also reduced the average size of visceral adipocytes in HFD mice (Figure 3C,D). HFD mice had greater calorie intake compared to LFD mice, but there were no significant differences in food consumption between the HFD and HFD-ALS mice (Figure 3E).

![Figure 3. Effects of ALS-L1023 on body weight, visceral fat mass, visceral adipocyte size, and food consumption in HFD mice. Adult male C57BL/6J mice were fed a low-fat diet (LFD), a high-fat diet (HFD) or HFD supplemented with ALS-L1023 (HFD-ALS) for 15 weeks. (A) body weights at the end of the treatment period are significantly different between the LFD group and the HFD group (# p < 0.05) and between the HFD group and the group fed a HFD supplemented with ALS-L1023 (* p < 0.05); (B) visceral adipose tissue mass and (C) epididymal adipocyte size; (D) representative hematoxylin-eosin-stained sections (5 μm thick) of epididymal adipose tissues are shown (original magnification ×100); (E) effects of ALS-L1023 on food intake. All values are expressed as the mean ± SD (n = 8/group). # p < 0.05 compared with LFD. * p < 0.05 compared with HFD.]}
2.4. Effects of ALS-L1023 on Serum ALT, AST, and Lipid Levels in HFD Mice

HFD feeding increased serum concentrations of alanine transaminase (ALT) and aspartate transaminase (AST) compared with LFD, but HFD-ALS mice had substantially lower ALT and AST levels than HFD mice (Figure 4A,B). ALS-L1023 treatment also reduced serum lipid levels including triglycerides, free fatty acids, and total cholesterol in HFD mice (Figure 4C–E).

![Bar charts showing changes in serum ALT, AST, triglycerides, free fatty acids, and total cholesterol levels in LFD, HFD, and HFD-ALS mice.](image)

**Figure 4.** Changes in circulating ALT, AST and lipid levels in HFD mice. Adult male C57BL/6J mice were fed a low-fat diet (LFD), a high-fat diet (HFD) or HFD supplemented with ALS-L1023 (HFD-ALS) for 15 weeks. Serum levels of (A) alanine aminotransferase (ALT) and (B) aspartate transaminase (AST); serum levels of (C) triglycerides; (D) free fatty acids and (E) total cholesterol. All values are expressed as the mean ± SD (n = 8/group). *p < 0.05 compared with LFD. *p < 0.05 compared with HFD.
2.5. Effects of ALS-L1023 on Obesity-Induced NAFLD in HFD Mice

Hematoxylin-eosin-stained liver sections showed that HFD mice developed marked microvesicular and macrovesicular steatosis (Figure 5A). However, ALS-L0123 treatment almost completely abolished intrahepatic triglyceride contents in HFD mice. Liver sections were stained with toluidine blue to detect mast cells. Infiltration of mast cells into livers was evident in HFD mice, but ALS-L1023 decreased the number of hepatic mast cells (Figure 5B). Liver sections were also stained with an antibody against CD68, which is expressed on macrophages and monocytes. CD68-positive cells were decreased in HFD-ALS mice than in HFD mice (Figure 5C). Masson’s trichrome-stained sections showed that liver collagen levels were eminent in HFD mice (Figure 5D). In contrast, ALS-L1023 inhibited HFD-induced increases in hepatic collagen levels. The distribution of α-smooth muscle actin (α-SMA)-positive cells during hepatic fibrosis was studied in HFD-fed mice. Hepatic α-SMA-positive cells were observed in perisinusoidal space and fibrous septa, and ultimately surrounded regenerative nodules in HFD mice (Figure 5E). However, ALS-L1023 treatment resulted in α-SMA-positive cell reductions.

![Figure 5](https://example.com/figure5.png)

Figure 5. Effects of ALS-L1023 on liver histology in HFD mice. Adult male C57BL/6J mice were fed a low-fat diet (LFD), a high-fat diet (HFD) or HFD supplemented with ALS-L1023 (HFD-ALS) for 15 weeks. (A) hematoxylin and eosin-stained sections of liver tissues (original magnification ×100); (B) toluidine blue-stained sections of liver tissues (original magnification ×400); (C) immunohistochemical detection of CD68-positive macrophages in the liver (original magnification ×200); (D) Masson’s trichrome-stained sections of liver tissues (original magnification ×100); (E) liver sections stained with an antibody against α-smooth muscle actin (α-SMA) (original magnification ×200). All values are expressed as the mean ± SD (n = 10/group).

2.6. Effects of ALS-L1023 on Liver Expression of Genes Involved in NAFLD in HFD Mice

To evaluate whether inhibitory effects of ALS-L1023 on hepatic steatosis in obese mice were associated with alterations of the expression of genes targeted by peroxisome proliferator-activated receptor α (PPARα), we measured mRNA levels of PPARα target genes such as fatty acyl-CoA oxidase (ACOX), carnitine palmitoyltransferase I (CPT-I), medium-chain acyl-CoA dehydrogenase
(MCAD), and very long-chain acyl-CoA dehydrogenase (VLCAD), which encode enzymes involved in fatty acid β-oxidation. Expression of these genes was higher in HFD-ALS mice than in HFD mice (Figure 6A). We also analyzed the effects of ALS-L0123 on mRNA levels of genes involved in lipogenesis, such as fatty acid synthase (FAS), peroxisome proliferator-activated receptor γ (PPARγ), and sterol regulatory element-binding protein 1c (SREBP-1c). FAS and SREBP-1c mRNA levels were reduced in HFD-ALS mice compared with those in HFD mice (Figure 6B). We also examined hepatic expression of genes involved in cholesterol production, such as farnesoid X receptor (FXR) and HMG-CoA reductase (HMGCR). Hepatic mRNA levels of FXR and HMGCR genes were decreased in HFD mice compared with LFD mice (Figure 6C). In contrast, ALS-L1023 treatment increased HMGCR mRNA levels in HFD controls. Hepatic inflammation is increased by expression in hepatocytes of inflammatory genes including tumor necrosis factor α (TNFα), CD68, monocyte chemoattractant protein 1 (MCP-1), macrophage receptor with collagenous structure (MARCO), intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1). Expression analysis of these genes showed that ALS-L0123 decreased mRNA levels of TNFα, CD68, MCP-1, MARCO, ICAM-1, and VCAM-1 in livers of HFD mice (Figure 6D). Hepatic fibrosis is induced by fibrogenic molecules, such as α-SMA, transforming growth factor β (TGFβ), and collagen α1. HFD-ALS reduced mRNA levels of TGFβ, α-SMA, and collagen α1 compared with HFD (Figure 6E). Nuclear factor E2-related factor 2 (Nrf2) and superoxide dismutase 2 (SOD2) are major regulators of the oxidative stress defense. HFD reduced Nrf2 mRNA levels compared with LFD, but HFD-ALS increased SOD2 expression compared with HFD (Figure 6F). B cell lymphoma 2 (Bcl-2), caspase 3, and caspase 8 are involved in the regulation of cell death. HFD decreased Bcl-2 mRNA levels compared with LFD, whereas HFD-ALS increased Bcl-2 mRNA levels compared with HFD (Figure 6G).

**A. Fatty acid oxidation**

**B. Lipogenesis**

**C. Cholesterol production**

**D. Inflammation**

Figure 6. Cont.
We investigated the effects of ALS-L1023 on epididymal adipose tissue inflammation, which is the tissue type most susceptible to the development of inflammation during HFD-induced obesity. Fifteen weeks of HFD feeding resulted in the organization of macrophages into crown-like structures—the organization of macrophages in a crown around single adipocytes—in epididymal adipose tissues of HFD-ALS mice. To confirm the macrophage infiltration in epididymal adipose tissues, we stained adipose tissue sections with an antibody against CD68. HFD-ALS mice had less macrophage infiltrates in epididymal adipose tissues than HFD mice (Figure 7C). Expression analysis of inflammatory genes in epididymal adipose tissues showed that mRNA levels of TNFα, CD68, and MCP-1 were lower in HFD-ALS mice than in HFD mice (Figure 7C).
was increased in VAT. These results are in agreement with our previous results showing that the anti-angiogenic herbal composition Ob-X decreased blood-vessel density and the expression of angiogenic factors in VAT of obese mice [7].

Consistent with its effects on VAT vasculature, the administration of ALS-L1023 to obese mice decreased angiogenesis was lowered in HFD-ALS mice. Consistent with its effects on VAT vasculature, the administration of ALS-L1023 to obese mice decreased endothelial (vWF-positive) cells within VAT was significantly reduced in HFD-ALS mice compared with HFD obese mice. The real-time imaging of microcirculation showed that VAT angiogenesis was lowered in HFD-ALS mice. Consistent with its effects on VAT vasculature, the administration of ALS-L1023 to obese mice decreased endothelial (vWF-positive) cells within VAT was significantly reduced in HFD-ALS mice compared with HFD obese mice.

Our results demonstrate that the anti-angiogenic lemon-balm extract ALS-L1023 can ameliorate obesity-induced NAFLD by improving VAT function.

Newly formed adipose tissue depends on continued angiogenesis for further growth. Different angiogenesis inhibitors significantly reduced body weight and adipose tissue mass [23,24], indicating a role of angiogenesis in adipose tissue growth. Based on these reports, we primarily examined anti-angiogenic activities of ALS-L1023 and found that ALS-L1023 inhibited HUVEC tube formation in vitro. ALS-L1023 reduced the formation of capillary-like tubular networks, but this reduction was reversed by VEGF and FGF. VEGF and FGF are angiogenic stimulators that induce the proliferation and migration of endothelial cells. Therefore, the anti-angiogenic effects of ALS-L1023 were most likely the result of inhibited endothelial-cell proliferation and migration. Our in vivo angiogenesis studies revealed that ALS-L1023 also inhibited VAT vasculature. The number of endothelial (vWF-positive) cells within VAT was significantly reduced in HFD-ALS mice compared with HFD obese mice.

The real-time imaging of microcirculation showed that VAT angiogenesis was lowered in HFD-ALS mice. Consistent with its effects on VAT vasculature, the administration of ALS-L1023 to obese mice decreased VEGF-A mRNA expression, whereas the anti-angiogenic TSP-1 mRNA expression was increased in VAT. These results are in agreement with our previous results showing that the anti-angiogenic herbal composition Ob-X decreased blood-vessel density and the expression of angiogenic factors in VAT of obese mice [7].

Figure 7. Epididymal adipose tissue inflammation of HFD-ALS mice. Adult male C57BL/6J mice were fed a low-fat diet (LFD), a high-fat diet (HFD) or HFD supplemented with ALS-L1023 (HFD-ALS) for 15 weeks. (A) hematoxylin and eosin-stained sections of epididymal adipose tissues (original magnification ×100); (B) immunohistochemical detection of CD68+ macrophages in epididymal adipose tissues (original magnification ×200); (C) the mRNA expression of inflammatory factors in epididymal adipose tissues. All values are expressed as mean ± SD (n = 6/group)). * p < 0.05 compared with LFD. * p < 0.05 compared with HFD. MCP-1, monocyte chemoattractant protein 1; TNFα, tumor necrosis factor α.
ALS-L1023 significantly reduced body weight and VAT mass in HFD mice, which was consistent with previous results indicating that several types of angiogenesis inhibitors, such as angiostatin, endostatin, and TNP-470, inhibit expansion of fat mass in mice [23,24]. Furthermore, ALS-L1023 reduced the average size of visceral adipocytes. However, significant differences in calorie intake were not observed between the HFD and HFD-ALS mice. These results show that anti-angiogenic weight loss may occur without appetite changes. Visceral adipocyte hypertrophy is closely associated with metabolic syndromes including insulin resistance, type 2 diabetes, and cardiovascular disease by secreting several kinds of adipokines [25,26]. HFD-ALS mice exhibited significant reductions in serum glucose levels during intraperitoneal glucose tolerance test compared with HFD mice (data not shown). Given that adipogenesis and obesity are closely associated with angiogenesis, modulating angiogenesis may be a novel therapeutic approach to obesity and obesity-related diseases [27].

It has been shown that increased visceral/intra-abdominal fat is a marker of increased ectopic fat in other sites, such as the liver and heart [14]. In addition, visceral fat accumulation is linked to obesity comorbidities and increased risk of hepatic disease [28]. A wide range of NAFLD states are associated with intra-abdominal fat mass in both men and women, independently of subcutaneous fat levels [29]. Mulder et al. reported that HFD feeding between 12 and 24 weeks, the period in which epididymal white adipose tissue became inflamed and did not expand further, coincided with hepatic steatosis and preceded the development of NASH [13]. We observed that 15 weeks of HFD feeding induced significant lipid accumulation in liver. However, it was suppressed by ALS-L1023; reduced fat accumulation in liver was consistent with loss in adipose tissue mass and body weight. Moreover, larger adipocytes are hypothesized to cause an inflammatory response that ultimately leads to ectopic fat deposition [30]. This means that anti-angiogenic-induced VAT reduction may decrease obesity-induced hepatic steatosis.

The main causes of fat accumulation in the cytoplasm of hepatocytes (i.e., steatosis) are thought to be increased fatty-acid synthesis and decreased fatty-acid oxidation [31]. Previous studies investigated the role of PPARα in hepatic triglyceride accumulation as a major factor in fatty-acid oxidation in liver. PPARα generally activates a suite of target genes involved in fatty-acid uptake, β-oxidation, and transport in mitochondria and peroxisomes [32]. PPARα-induced fatty-acid catabolism might prevent hepatic fat deposition. ALS-L0123 treatment increased mRNA levels of fatty acid-oxidizing enzymes such as ACOX, CPT-1, MCAD, and VLCAD in HFD obese mice. De novo lipogenesis also plays a substantial role in NAFLD pathogenesis. De novo lipogenesis contributes 26% of liver triglyceride content in patients with NAFLD, but it contributes less than 5% of liver triglyceride content in healthy individuals [8,33]. Expression of lipogenic enzyme FAS and its regulator SREBP-1c was decreased in livers of HFD-ALS mice. In addition, ALS-L1023 did not decrease hepatic expression of FXR and HMGCR that are negative regulators of cholesterol synthesis, suggesting that inhibition of hepatic steatosis may not be due to decreased cholesterol synthesis. Thus, hepatic steatosis may be regulated in part through increased fatty-acid oxidation and decreased de novo lipogenesis during anti-angiogenic-induced hepatic steatosis.

The obese state is characterized by white adipose tissue dysfunction, that is, adipocyte hypertrophy, macrophage infiltration, and elevated expression of inflammatory genes. Adipocyte hypertrophy is a factor in determining macrophage infiltration of white adipose tissue [16,34]. Adipose tissue in lean individuals usually consists of approximately 5–10% macrophages, whereas that in obese individuals can consist of up to 50% macrophages [34]. Adipocyte hypertrophy is associated with the formation of crown-like structures—the arrangements of macrophages in a “crown” around single, large adipocytes [14,35]. More than 90% of all macrophages in white adipose tissue of obese humans and mice are localized to dead adipocytes, suggesting that formation of crown-like structures exhibits features of necrosis in dead-like adipocytes [36]. We observed pronounced inflammation, indicated by CD68-positive macrophages and crown-like structures around adipocytes in epididymal adipose tissues during 15 weeks of HFD-induced obesity. In contrast to our data, Ishimoto et al. reported that HFD induced hepatic steatosis, but not inflammation or fibrosis [18]. This difference may be due to
differences in HFD composition. HFD diet is composed of 36% fat-derived calories (9% corn oil and 27% butter) in their experiments, whereas 45% fat-derived calories (5.6% soybean oil and 39.4% lard) in our experiments. Enhanced expression of inflammatory genes is directly related to white adipose tissue dysfunction in obese individuals [35]. In our study, HFD obese mice exhibited increased expression of inflammatory marker genes such as TNFα, CD68, and MCP-1 compared with LFD mice, but ALS-L1023 reduced mRNA expression of these genes in HFD mice. The portal hypothesis suggests that omental adipose tissue is drained by the portal venous system and has a direct circulating connection with liver. Thus, deregulation of fatty-acid and inflammatory-cytokine production by omental adipose tissues in obese individuals might have an impact on liver function [14,15]. These results suggest that the anti-angiogenic reduction of adipose inflammation may lead to inhibition of NAFLD.

Adipose tissue dysfunction might signal progression of hepatic steatosis toward NASH [16]. Increased infiltration of macrophages in omental adipose tissue was associated with marked hepatic lesions in morbidly obese humans [14]. In that report, the presence of macrophages in omental adipose tissues participated in the cellular mechanisms favoring hepatic fibroinflammatory lesions in obese patients. We also observed the induction of lobular inflammation in HFD mice. CD68-positive macrophages and toluidine blue-stained mast cells were prominent in livers of HFD mice. However, the number of CD68-positive cells and mast cells was reduced in livers of HFD-ALS mice. Our results are in agreement with a previous report showing that surgical removal of inflamed epididymal adipose tissue attenuated the development of NASH in obese individuals [13]. We found that hepatic expression of inflammatory genes, such as TNFa, CD68, MCP-1, MARCO, ICAM-1, and VCAM-1, was decreased in HFD-ALS mice compared with HFD mice. These results suggest that angiogenesis inhibition can attenuate HFD-induced hepatic inflammation by repairing adipose tissue dysfunction in obese mice. In addition, obesity and NAFLD are also shown to be associated with alterations in intestinal microbiota. HFD and high-fructose diet cause gut dysbiosis that stimulates the influx of gut-derived endotoxin into the liver, leading to NAFLD development [37–39]. Similarly, there may be a cross-talk between gut microbiota and adipose tissue. Further studies will be necessary to examine whether ALS-L1023 protects gut-derived endotoxemia and, if so, regulates endotoxin-induced adipose tissue inflammation, resulting in the amelioration of obesity and NAFLD.

Liver fibrosis is the extensive accumulation of ECM proteins, including collagen, which occurs in most types of chronic liver disease. Our histological analysis revealed that HFD feeding induced significant perivascular fibrosis in livers. HFD obese mice showed hepatic collagen accumulation and expression of α-SMA, a marker of hepatic stellate cells that produce and deposit extracellular matrix, leading to progressive fibrosis. The amounts of collagen and α-SMA-positive cells were markedly decreased in HFD-ALS mice. ALS-L1023 also decreased mRNA expression of fibrogenic genes such as TGFβ, collagen α1, and α-SMA. VAT is reported to be directly associated with hepatic fibrosis [10]. Regarding associations between VAT and fibrosis, increased CT-measured visceral fat area is shown to be an independent risk factor for fibrosis and NASH [12]. These reports are in agreement with our results showing that anti-angiogenic reduction of VAT can contribute to the attenuation of hepatic fibrosis in obese mice.

It is well known that the HFD provokes oxidative stress in liver [40]. HFD mice decreased hepatic expression of the transcription factor Nrf2 that positively regulates antioxidant stress. In contrast, HFD-ALS mice increased hepatic expression of SOD2 that clears mitochondrial reactive oxygen species. Concomitantly, administration of ALS-L1023 to HFD mice increased mRNA levels of Bcl-2 which promotes cellular survival and inhibits the actions of pro-apoptotic proteins. These results suggest that ALS-L1023 may exert antioxidative response and antiapoptosis in livers of HFD mice by upregulating SOD2 and Bcl-2.

Circulating markers of liver injury were reduced and lipid metabolism was improved in HFD-ALS mice. HFD feeding induced liver damage and elevated circulating ALT and AST levels [41], but ALS-L1023 decreased serum ALT and AST levels in HFD mice. ALS-L1023 also decreased serum levels of free fatty acids, triglycerides, and total cholesterol in HFD mice. The changes in lipid levels
occurred in parallel with changes in VAT mass and adipocyte size following ALS-L1023 treatment. These results suggest that anti-angiogenic treatment improves liver function and lipid metabolism.

Despite the large numbers of drugs used to treat NAFLD, dietary and exercise therapies are still most effective against NAFLD. While chronic intake of fructose, high fat, and high cholesterol induce obesity and NAFLD, Mediterranean diet improves BMI and NAFLD [18, 19, 42, 43]. High-density aerobic exercise is also beneficial for improving obesity and NAFLD [44]. Because NAFLD occurs primarily in obese patients, weight loss through lifestyle intervention, bariatric surgery, and drugs is the first-line treatment for all NAFLD patients. Current potential medications for NAFLD include insulin sensitizers such as metformin and thiazolidinediones (pioglitazone and rosiglitazone), lipid-lowering drugs (atorvastatin, fenofibrate, and ezetimibe), antioxidants (vitamin E and pentoxifylline), glucagon-like peptide 1 analogues (exenatide), ursoodeoxycholine acid, obeticholic acid, and ω-3 fatty acids [45]. Since long-term use of these drugs, however, causes side effects, such as cancer, vascular disease, and depression, there is a need for safe and effective therapies against NAFLD.

4. Materials and Methods

4.1. Preparation of ALS-L1023

ALS-L1023 was manufactured by activity-guided fractionation from Melissa officinalis L. leaves that were purchased from Alfred Galke GmbH, (Harz, Germany). Dried Melissa leaves were extracted with aqueous ethanol and the extract was filtered and concentrated. The concentrated ethanol extract was further fractionated with ethyl acetate, concentrated and dried to obtain ALS-L1023 in a dried powder form. A voucher specimen of Melissa officinalis (AL-20121015-001-R) was deposited at the AngioLab Inc. (Daejeon, Korea). ALS-L1023 was standardized with two reference compounds of rosmarinic acid and caffeic acid by high-performance liquid chromatography [22], and then dissolved in 100% dimethyl sulfoxide and used for in vitro tests.

4.2. In Vitro Cytotoxicity Test

HUVECs were purchased from Lonza (Basel, Switzerland) and cultured in EBM-2 supplemented with SingleQuots (Lonza) in a 37 °C incubator with a humidified atmosphere containing 5% CO₂. Cells were plated on a 96 well plate at a density of 1 × 10⁴ cells/well and incubated for 24 h at 37 °C with culture medium in the presence of ALS-L1023. Cell viability was detected by 2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxanilide disodium salt (XTT) assay using a Cell Proliferation Kit II (Roche, Basel, Switzerland).

4.3. In Vitro HUVEC Tube Formation Assay

HUVECs were cultured in EBM-2 supplemented with SingleQuots in a 37 °C incubator containing 5% CO₂. 200 µL of Matrigel (BD Biosciences, Bedford, MA, USA) was pipetted into the wells of a 48-well plate and allowed to solidify for 1 h at 37 °C. HUVECs were plated on Matrigel-coated wells at a density of 4 × 10⁴ cells/well and incubated for 16 h at 37 °C with medium containing ALS-L1023, TNP-470, ALS-L1023 plus VEGF or ALS-L1023 plus FGF. The formation of capillary-like tubular networks was observed with an inverted microscope. The percentage of tubule area was quantified by image analysis using Image-Pro Plus (Media Cybernetics, Bethesda, MD, USA).

4.4. Animal Studies

Male 10-week-old wild-type C57BL/6J mice (n = 8/group) were purchased from SLC (Shizuoka, Japan) and randomly divided into three groups, which were fed for 15 weeks with an LFD (13kcal % fat, Research Diets, New Brunswick, NJ, USA), HFD (45kcal % fat, Research Diets), or HFD supplemented with ALS-L1023 (0.8%, w/w) (HFD-ALS). Body weights were measured daily by a person blinded to each treatment group. After an 8 h fast on the last day of the study, the animals were sacrificed by cervical dislocation. Blood was collected from the retroorbital sinus into tubes, and serum was
separated and stored at −80 °C until analysis. VAT was collected from epididymal, retroperitoneal, and mesenteric white adipose tissues. Liver and epididymal adipose tissues were frozen quickly in liquid nitrogen and stored at −80 °C until extraction of total RNA. Portions were prepared for histology. All animal experiments were approved by the Institutional Animal Care and Use Committees of Mokwon University (permit number: NVRGS AEC-9), and followed National Research Council Guidelines.

4.5. Serum Analysis

Levels of ALT, AST, total cholesterol, and triglycerides were measured using an automatic blood chemical analyzer (Hitachi, Tokyo, Japan). Levels of free fatty acids were measured using SICDIA NEFAZYME (Shinyang Chemical, Seoul, Korea).

4.6. Histological Analysis

Tissue specimens were fixed in 10% phosphate-buffered formalin for 1 day and embedded in paraffin. To analyze hepatic steatosis, inflammation, and fibrosis, liver-tissue sections (5 µm) were cut and stained with hematoxylin-eosin, toluidine blue, and Masson’s trichrome, respectively. To measure adipocyte size and crown-like structures, epididymal adipose tissues were stained with hematoxylin-eosin and counting was performed blindly by three independent observers. Stained preparations were examined using an image analysis system (Image Pro-Plus).

4.7. Immunohistochemistry

Blood-vessel staining was performed using a blood-vessel staining kit (Chemicon, Billerica, MA, USA). Epididymal adipose tissues were fixed in 10% phosphate-buffered formalin for one day and processed in a routine manner for paraffin sections. Sections of 3-µm thickness were cut and irradiated in a microwave oven for epitope retrieval. Sections were incubated with a rabbit anti-von vWF antibody as a primary antibody, goat anti-rabbit antibody as a secondary antibody, and streptavidin-alkaline phosphatase solution. A freshly prepared chromogen reagent was added to sections for the visualization of blood vessel. Blood-vessel density was normalized with the number of adipocytes.

Infiltrated macrophages and collagen accumulation were detected using a monoclonal mouse anti-CD68 antibody (ab955, Abcam, Cambridge, UK) and a monoclonal mouse anti-α-SMA antibody (ab7817, Abcam), respectively. Irradiated liver-tissue sections were incubated with CD68 (1:200 dilution) and α-SMA (1:150 dilution) primary antibodies and an anti-mouse IgG biotinylated secondary antibody (Vector Laboratories, Burlingame, CA, USA), and diaminobenzidine (Vector Laboratories) as a color substrate. Irradiated epididymal adipose tissue sections were immunostained with an anti-CD68 antibody and counterstained with Mayer’s hematoxylin.

4.8. FCFM

Visualization of real-time visceral adipose tissue vasculature was performed using an FCFM imaging system (Cellvizio, Mauna Kea Technologies, Paris, France) with excitation and emission wavelengths of 488 and 520 nm, respectively. Fluorescein isothiocyanate-dextran (MW 70 kDa, 500 mg/kg, 100 µL) was injected intravenously immediately prior to FCFM imaging to visualize the microvascular network. A small incision was made to insert the laser probe. Images and videos were analyzed using Cellvizio dual viewer (Cellvizio) and all movies were processed using a software (ImageCell, Mauna Kea Technologies).

4.9. Quantitative Real-Time Polymerase Chain Reaction (PCR)

Total cellular RNA from liver and gonadal adipose tissues was prepared using Trizol reagent (Gibco-BRL, Grand Island, NY, USA) according to the manufacturer’s instructions. Total cellular RNA (2 µg) was reverse transcribed using Moloney murine leukemia virus reverse transcriptase to generate
an antisense cDNA template. The genes of interest were amplified from the synthesized cDNA using AccuPower® GreenStar™ qPCR PreMix (Bioneer, Deajeon, Korea) on an Excycler™ 96 Real Time Quantitative Thermal Block machine (Bioneer). The PCR primers used for gene expression analysis are shown in Table 1. PCR was performed using the following conditions: denaturing at 95 °C for 5 min followed by 50 cycles of 95 °C for 10 s, 60 °C for 40 s, and 72 °C for 10 s. Transcript concentrations were calculated as copies per µL using a standard curve, and the relative expression levels were calculated as the ratio of target gene cDNA to β-actin cDNA.

Table 1. Sequences of primers used for quantitative real-time PCR assays.

| Genes | Gene Bank | Primer Sequences |
|-------|-----------|------------------|
| ACOX  | NM_001271898 | Forward: 5'-GCACATTGGCATTGGATAC-3'  
Reverse: 5'-CACATTGGCATTGGATAC-3' |
| α-SMA | NM_007392 | Forward: 5'-CTGAGAAGAGCCTGGACTT-3'  
Reverse: 5'-CTGATCCACATCTGCTGGAAG-3' |
| Bcl-2  | NM_009741.5 | Forward: 5'-TCGCTACCGTCGTGACTTC-3'  
Reverse: 5'-AAACAGAGGTCGCATGCTG-3' |
| Caspase 3 | NM_009810.3 | Forward: 5'-ACGCAGCCAACCTCAGAGA-3'  
Reverse: 5'-ATGAACCACGACCCGTCCT-3' |
| Caspase 8 | NM_001277926.1 | Forward: 5'-TGCTTGGACTACATCCCACAC-3'  
Reverse: 5'-CCAACTCGCTCACTTCTTCTG-3' |
| CD68   | NM_009853 | Forward: 5'-AACAGGACCTACATCAGAGC-3'  
Reverse: 5'-CTGTAGCCTTAGAGAGAGCA-3' |
| Collagen α1 | NM_007742 | Forward: 5'-GCCCGAACCCCAAGGAAAAGC-3'  
Reverse: 5'-CTGGGAGGCCTCGGTGGACATTAG-3' |
| CPT-1  | L07736 | Forward: 5'-CTTGGTGCTGACTACAACC-3'  
Reverse: 5'-GCCCTCCCGTACACTCACTC-3' |
| FAS    | NM_007988 | Forward: 5'-CTTGGGTGCTGACTACAACC-3'  
Reverse: 5'-GCCCTCCCGTACACTCACTC-3' |
| FXR    | NM_001163504 | Forward: 5'-GCACATTGGCATTGGATAC-3'  
Reverse: 5'-CTGATCCACATCTGCTGGAAG-3' |
| HMGCR  | NM_008255.2 | Forward: 5'-CGAGGAAAGACTGTGGTTTG-3'  
Reverse: 5'-CACGTTCCTTGAAGATCTTG-3' |
| ICAM-1 | NM_010493 | Forward: 5'-AGCTACCGGACCAGATCC-3'  
Reverse: 5'-ATACAGCACTGCTCAGAATCC-3' |
| MARCO  | NM_010766 | Forward: 5'-GAAACAAAGGGACATGGG-3'  
Reverse: 5'-TTCACACCTGCAATCCCTG-3' |
| MCAD   | NM_007382 | Forward: 5'-GACATTITGGAAAGCTGGTGTG-3'  
Reverse: 5'-TCAGACTATGATACGGCTCCTG-3' |
| MCP-1  | NM_011331 | Forward: 5'-TGATTCCAATGACTGCTGAG-3'  
Reverse: 5'-ATGTCTGGACCCATTCCTT-3' |
| Nif-2  | NM_010902.4 | Forward: 5'-TGCCAGAGACATTCCTTATC-3'  
Reverse: 5'-GCTGCCACCTGCTCAGGG-3' |
| PPARγ  | NM_013124 | Forward: 5'-ATTCTCTGGGCCACACACCTTGGG-3'  
Reverse: 5'-TGGAACCTGGATGTTTCCATC-3' |
| SOD2   | NM_013671.3 | Forward: 5'-ATTAACGCACGATACATCAGA-3'  
Reverse: 5'-TGTCCTCCCCACATTGAATCTG-3' |
| SREBP-1c | BC056922 | Forward: 5'-CTTCTTGAGACATCGCAAA-3'  
Reverse: 5'-GGTACGACGAGAAGCCCCATC-3' |
| TGFβ   | NM_011577 | Forward: 5'-ATCCACACCCACATGCTT-3'  
Reverse: 5'-GATTTGACCTCCTTATCCAG-3' |
| TNFα   | NM_001278601 | Forward: 5'-GCCAGTTGCTATTTCTGAGTATG-3'  
Reverse: 5'-ACATCTGAGCCCTCAGGAATTG-3' |
| VCAM-1 | NM_011693 | Forward: 5'-CGTCAAGAGGGTACTTCTTGGT-3'  
Reverse: 5'-CATGGACTCTAGTACATAGTGC-3' |
4.10. Statistical Analysis

Values are expressed as mean ± standard deviation (SD). Statistical analysis was performed using analysis of variance followed by Turkey’s post hoc tests. Statistical significance was defined as a p-value < 0.05.

5. Conclusions

In conclusion, the anti-angiogenic herbal extract ALS-L1023 reduces VAT mass and regulates VAT dysfunction, leading to attenuation of obesity-induced NAFLD and NASH. Several lines of evidence suggest that VAT is an independent risk factor for NAFLD with significant fibrosis or for NASH in patients with NAFLD. These relationships appear to be independent from other metabolic risk factors. Visceral obesity is probably the most important target for future interventions in patients with NAFLD. Thus, our results suggest that angiogenesis inhibitors targeting adipose tissue might be promising drugs for the treatment of NAFLD and NASH.

Acknowledgments: This work was supported by the National Research Foundation of Korea (NRF) Grant funded by the Korea Government (MEST) (2015R1A1A3A04001016) and the Korea Health Industry Development Institute (KHIDI) Grant funded by the Korea Government (MHW) (HI15C0075 and HI16C0753).

Author Contributions: Conceived and designed the experiments: Michung Yoon and Soon Shik Shin. Performed the experiments: Jeongjun Kim, Haerim Lee, Jonghoon Lim, and Jaeho Oh. Analyzed the data: Jeongjun Kim, Haerim Lee, Jonghoon Lim, Jaeho Oh, Soon Shik Shin, and Michung Yoon. Wrote the paper: Michung Yoon and Soon Shik Shin.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Folkman, J. Tumor angiogenesis. *Adv. Cancer Res.* 1985, 43, 175–203. [PubMed]
2. Celletti, FL.; Waugh, J.M.; Amabile, P.G.; Brendolan, A.; Hilfiker, P.R.; Dake, M.D. Vascular endothelial growth factor enhances atherosclerotic plaque progression. *Nat. Med.* 2001, 7, 425–429. [CrossRef] [PubMed]
3. Ferrara, N.; Davis-Smyth, T. The biology of vascular endothelial growth factor. *Endocr. Rev.* 1997, 18, 4–25. [CrossRef] [PubMed]
4. Crandall, D.L.; Hausman, G.J.; Kral, J.G. A review of the microcirculation of adipose tissue: Anatomic, metabolic, and angiogenic perspectives. *Microcirculation* 1997, 4, 211–232. [CrossRef] [PubMed]
5. Hobson, B.; Denekamp, J. Endothelial proliferation Endothelial proliferation in tumours and normal tissues: Continuous labelling studies. *Br. J. Cancer* 1984, 49, 405–413. [CrossRef] [PubMed]
6. Bouloumic, A.; Lolmède, K.; Sengenès, C.; Galitzky, J.; Lafontan, M. Angiogenesis in adipose tissue. *Ann. Endocrinol.* 2002, 63, 91–95.
7. Kim, M.Y.; Park, B.Y.; Lee, H.S.; Park, E.K.; Nahm, J.C.; Lee, J.; Hong, Y.; Choi, S.; Park, D.; Lee, H.; et al. The anti-angiogenic herbal composition Ob-X inhibits adipose tissue growth in obese mice. *Int. J. Obes.* 2010, 34, 820–830. [CrossRef] [PubMed]
8. Dowman, J.K.; Tomlinson, J.W.; Newsome, P.N. Pathogenesis of non-alcoholic fatty liver disease. *QJM* 2010, 103, 71–83. [CrossRef] [PubMed]
9. Alwahsh, S.M.; Dwyer, B.J.; Forbes, S.; Thiel, D.H.; Lewis, P.J.; Ramadori, G. Insulin production and resistance in different models of diet-induced obesity and metabolic syndrome. *Int. J. Mol. Sci.* 2017, 18, E285. [CrossRef] [PubMed]
10. Van der Poorten, D.; Milner, K.L.; Hui, J.; Hodge, A.; Trenell, M.I.; Kench, J.G.; London, R.; Peduto, T.; Chisholm, D.J.; George, J. Visceral fat: A key mediator of steatohepatitis in metabolic liver disease. *Hepatology* 2008, 48, 449–457. [CrossRef] [PubMed]
11. Jun, D.W.; Han, J.H.; Kim, S.H.; Jang, E.C.; Kim, N.I.; Lee, J.S.; Song, M.H.; Kim, S.H.; Jo, Y.J.; Park, Y.S. Association between low thigh fat and non-alcoholic fatty liver disease. *J. Gastroenterol. Hepatol.* 2008, 23, 888–893. [CrossRef] [PubMed]
12. Yu, S.J.; Kim, W.; Kim, D.; Yoon, J.H.; Lee, K.; Kim, J.H.; Cho, E.J.; Lee, J.H.; Kim, H.Y.; Kim, Y.J. Visceral Obesity Predicts Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. *Medicine* 2015, 94, e2159. [CrossRef] [PubMed]
12. Mulder, P.; Morrison, M.C.; Wielinga, P.Y.; van Duyvenvoorde, W.; Kooistra, T.; Kleemann, R. Surgical removal of inflamed epididymal white adipose tissue attenuates the development of non-alcoholic steatohepatitis in obesity. Int. J. Obes. 2016, 40, 675–684. [CrossRef] [PubMed]
13. Cancello, R.; Tordjman, J.; Poitou, C.; Guilhem, G.; Bouillot, J.L.; Hugol, D.; Coussieu, C.; Basdevant, A.; Bar Hen, A.; Bedossa, P. Increased infiltration of macrophages in omental adipose tissue is associated with marked hepatic lesions in morbid human obesity. Diabetes 2006, 55, 1554–1561. [CrossRef] [PubMed]
14. Smith, U. Abdominal obesity: A marker of ectopic fat accumulation. J. Clin. Investig. 2015, 125, 1790–1792. [CrossRef] [PubMed]
15. Shin, S.S.; Yoon, M. The herbal composition GGEx18 from Laminaria japonica, Rheum palmatum, and Ephedra sinica inhibits high-fat diet-induced hepatic steatosis via hepatic PPARα activation. Pharm. Biol. 2012, 50, 1261–1268. [CrossRef] [PubMed]
16. Ishimoto, T.; Lanaspa, M.A.; Rivard, C.J.; Roncal-Jimenez, C.A.; Orlicky, D.J.; Cicerchi, C.; McMahan, R.H.; Abdelmalek, M.F.; Rosen, H.R.; Jackman, M.R.; et al. High-fat and high-sucrose (western) diet induces steatohepatitis that is dependent on fructokinase. Hepatology 2013, 58, 1632–1643. [CrossRef] [PubMed]
17. Savard, C.; Tartaglione, E.V.; Kuver, R.; Haigh, W.G.; Farrell, G.C.; Subramanian, S.; Chait, A.; Yeh, M.M.; Quinn, L.S.; Ioannou, G.N. Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis. Hepatology 2013, 57, 81–92. [CrossRef] [PubMed]
18. Alwahsh, S.M.; Xu, M.; Schultze, F.C.; Wilting, J.; Mihm, S.; Raddatz, D.; Ramadori, G. Combination of alcohol and fructose exacerbates metabolic imbalance in terms of hepatic damage, dyslipidemia, and insulin resistance in rats. PLOS ONE 2014, 9, e104220. [CrossRef] [PubMed]
19. Park, B.Y.; Lee, H.; Woo, S.; Yoon, M.; Kim, J.; Hong, Y.; Lee, H.S.; Park, E.K.; Hahn, J.C.; Kim, J.W. Reduction of Adipose Tissue Mass by the Angiogenesis Inhibitor ALS-L1023 from Melissa officinalis. PLOS ONE 2015, 10, e0141612. [CrossRef] [PubMed]
20. Woo, S.; Yoon, M.; Kim, J.; Hong, Y.; Shin, S.S.; Yoon, M. The anti-angiogenic herbal extract from Melissa officinalis inhibits adipogenesis in 3T3-L1 adipocytes and suppresses adipocyte hypertrophy in high fat diet-induced obese C57BL/6 mice. J. Ethnopharmacol. 2016, 178, 1360–1369. [CrossRef] [PubMed]
21. Rupnick, M.A.; Panigray, D.; Zhang, C.; Dallabrida, S.M.; Lowell, B.B.; Langer, R.; Folkman, M.J. Adipose tissue mass can be regulated through the vasculature. Proc. Natl. Acad. Sci. USA 2002, 99, 10730–10735. [CrossRef] [PubMed]
22. Bräkenhielm, E.; Cao, R.; Gao, B.; gelin, B.; Cannon, B.; Parini, P.; Cao, Y. Angiogenesis inhibitor, TNP-470, prevents diet-induced and genetic obesity in mice. Circ. Res. 2004, 94, 1579–1588. [CrossRef] [PubMed]
23. Després, J.P.; Lemieux, I. Abdominal obesity and metabolic syndrome. Nature 2006, 444, 881–887. [CrossRef] [PubMed]
24. Jeong, S.; Yoon, M. Fenofibrate inhibits adipocyte hypertrophy and insulin resistance by activating adipose PPARα in high fat diet-induced obese mice. Exp. Mol. Med. 2009, 41, 397–405. [CrossRef] [PubMed]
25. Cao, Y. Angiogenesis modulates adipogenesis and obesity. J. Clin. Investig. 2007, 117, 2362–2368. [CrossRef] [PubMed]
26. Diehl, A.M. Hepatic complications of obesity. Gastroenterol. Clin. N. Am. 2005, 34, 45–61. [CrossRef] [PubMed]
27. Westerbacka, J.; Cornér, A.; Tiikkainen, M.; Tamminen, M.; Vehkavaara, S.; Häkkinen, A.M.; Fredriksson, J.; Yki-Järvinen, H. Women and men have similar amounts of liver and intra-abdominal fat, despite more subcutaneous fat in women: Implications for sex differences in markers of cardiovascular risk. Diabetologia 2004, 47, 1360–1369. [CrossRef] [PubMed]
28. Blüher, M. Adipose tissue dysfunction in obesity. Exp. Clin. Endocrinol. Diabetes 2009, 117, 241–250. [CrossRef] [PubMed]
29. Reddy, J.K.; Rao, M.S. Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. Am. J. Physiol. Gastrointest. Liver Physiol. 2006, 290, G852–G858. [CrossRef] [PubMed]
30. Yoon, M. The role of PPARα in lipid metabolism and obesity: Focusing on the effects of estrogen on PPARα actions. Pharmacol. Res. 2009, 60, 151–159. [CrossRef] [PubMed]
33. Donnelly, K.L.; Smith, C.I.; Schwarzenberg, S.J.; Jessurun, J.; Boldt, M.D.; Parks, E.J. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. *J. Clin. Invest.* **2005**, *115*, 1343–1351. [CrossRef] [PubMed]

34. Weisberg, S.P.; McCann, D.; Desai, M.; Rosenbaum, M.; Leibel, R.L.; Ferrante, A.W., Jr. Obesity is associated with macrophage accumulation in adipose tissue. *J. Clin. Invest.* **2003**, *112*, 1796–1808. [CrossRef] [PubMed]

35. Cancello, R.; Henegar, C.; Viguerie, N.; Taleb, S.; Poitou, C.; Rouault, C.; Coupaye, M.; Pelloux, V.; Hugol, D.; Bouillot, J.L.; et al. Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. *Diabetes* **2005**, *54*, 2277–2286. [CrossRef] [PubMed]

36. Cinti, S.; Mitchell, G.; Barbatelli, G.; Murano, I.; Ceresi, E.; Faloia, E.; Wang, S.; Fortier, M.; Greenberg, A.S.; Obin, M.S. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. *J. Lipid. Res.* **2005**, *46*, 2347–2355. [CrossRef] [PubMed]

37. Spruss, A.; Kanuri, G.; Wagnerberger, S.; Haub, S.; Bischoff, S.C.; Bergheim, I. Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice. *Hepatology* **2009**, *50*, 1094–1104. [CrossRef] [PubMed]

38. De Minicis, S.; Rychlicki, C.; Agostinelli, L.; Saccomanno, S.; Candelaresi, C.; Trozzi, L.; Mingarelli, E.; Facinelli, B.; Magi, G.; Palmieri, C.; et al. Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice. *Hepatology* **2014**, *59*, 1738–1749. [CrossRef] [PubMed]

39. Alwahsh, S.M.; Xu, M.; Seyhan, H.A.; Ahmad, S.; Mihm, S.; Ramadori, G.; Schultz, F.C. Diet high in fructose leads to an overexpression of lipocalin-2 in rat fatty liver. *World J. Gastroenterol.* **2014**, *20*, 1807–1821. [CrossRef] [PubMed]

40. Jabri, M.A.; Sakly, M.; Marzouki, L.; Sebai, H. Chamomile (*Matricaria recutita* L.) decoction extract inhibits in vitro intestinal glucose absorption and attenuates high fat diet-induced lipotoxicity and oxidative stress. *Biomed. Pharmacother.* **2017**, *87*, 153–159. [CrossRef] [PubMed]

41. Cui, B.; Liu, S.; Lin, X.; Wang, J.; Li, S.; Wang, Q.; Li, S. Effects of *Lycium barbarum* aqueous and ethanol extracts on high-fat-diet induced oxidative stress in rat liver tissue. *Molecules* **2011**, *16*, 9116–9128. [CrossRef] [PubMed]

42. Alwahsh, S.M.; Gebhardt, R. Dietary fructose as a risk factor for non-alcoholic fatty liver disease (NAFLD). *Arch. Toxicol.* **2017**, *91*, 1545–1563. [CrossRef] [PubMed]

43. Cakir, M.; Akbulut, U.E.; Okten, A. Association between Adherence to the Mediterranean Diet and Presence of Nonalcoholic Fatty Liver Disease in Children. *Child Obes.* **2016**, *12*, 279–285. [CrossRef] [PubMed]

44. Oh, S.; So, R.; Shida, T.; Matsu, T.; Kim, B.; Akiyama, K.; Isobe, T.; Okamoto, Y.; Tanaka, K.; Shoda, J. High-Intensity Aerobic Exercise Improves Both Hepatic Fat Content and Stiffness in Sedentary Obese Men with Nonalcoholic Fatty Liver Disease. *Sci. Rep.* **2017**, *7*, 43029. [CrossRef] [PubMed]

45. Hsu, W.F.; Sheen, L.Y.; Lin, H.J.; Chang, H.H. A Review of Western and Traditional Chinese Medical Approaches to Managing Nonalcoholic Fatty Liver Disease. *Evid. Based Complement. Alternat. Med.* **2016**, *2016*, 6491420. [CrossRef] [PubMed]